| Literature DB >> 35046715 |
Li Xue1, Li Tao1, Haifeng Sun2, Yan Wang1, Yanping Zhang1, Na Lei1, Zeshi Liu1, Hua Zhang1, Li Jin1, Ting Zhang1, Jing Zhang1, Hao Meng1, Fang Huang1, Yan Geng1, Ming Li3.
Abstract
BACKGROUND: Platelet (PLT) and red blood cell (RBC) have been demonstrated to play a critical role in inflammatory processes. This study aimed to evaluate the association of blood PLT and RBC related parameters with the disease activity in rheumatoid arthritis (RA) patients, and also to investigate the role of these indices in differentiating among RA patients with different disease activity.Entities:
Keywords: hemoglobin; platelets; red blood cells; rheumatoid arthritis
Year: 2022 PMID: 35046715 PMCID: PMC8763267 DOI: 10.2147/IJGM.S351505
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Comparison of Clinical Characteristics Between RA Patients and Controls
| RA (N=178) | Control (N=164) | ||
|---|---|---|---|
| Age (years) | 57.11±14.17 | 54.86±10.59 | 0.122 |
| Gender (F/M) | 132/46 | 126/38 | 0.616 |
| BMI (kg/m2) | 25.6±3.1 | 26.1±3.3 | 0.376 |
| CRP (mg/L) | 18.35(6.75–52.41) | 2.1(1.1–3.2) | < 0.001 |
| ESR (mm/h) | 37.0(15–79) | 5.22(2.73–12.81) | < 0.001 |
| RF (IU/mL) | 167.31(23.2–426.00) | 4.87(3.10–15.70) | < 0.001 |
| Anti-CCP (U/mL) | 246.3 (38.1–400.0) | 13.2(5.7–19.3) | < 0.001 |
| WBC (109/L) | 6.21±2.77 | 6.19±2.54 | 0.955 |
| RBC (1012/L) | 4.06±0.93 | 4.62±0.74 | < 0.001 |
| Hb (g/L) | 115.20± 28.08 | 136.18±21.67 | < 0.001 |
| HCT (%) | 35.45±8.59 | 41.03±5.84 | < 0.001 |
| RDW | 14.16±4.42 | 13.45±2.42 | 0.075 |
| PLT(109/L) | 240.59± 73.28 | 205.05±53.05 | < 0.001 |
| PDW | 12.42±4.41 | 12.97±3.90 | 0.263 |
| RPR | 0.019±0.0065 | 0.024±0.0072 | < 0.001 |
| HPR | 0.55±0.21 | 0.727±0.23 | < 0.001 |
Abbreviations: F, female; M, male; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide; WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; HCT, red blood cell specific volume; RDW, red blood cell volume distribution width; PLT, platelet; PDW, platelet volume distribution width; RPR, red blood cells-platelet ratio; HPR, hemoglobin–platelet ratio.
Comparison of Clinical Characteristics Between the Two RA Subgroups
| Inactive RA (N=88) | Active RA (N=90) | ||
|---|---|---|---|
| Age (years) | 56.29±15.16 | 58.41±13.33 | 0.121 |
| Gender (F/M) | 67/21 | 68/22 | 0.928 |
| BMI (kg/m2) | 25.5±3.1 | 24.7±2.3 | 0.325 |
| Disease duration (years) | 7.2±3.8 | 8.6±5.1 | 0.213 |
| CRP (mg/L) | 9.65(4.92–18.35) | 32.07(9.13–55.72) | < 0.001 |
| ESR (mm/h) | 30.0(14–65) | 54.0(19–87) | < 0.001 |
| RF (IU/mL) | 129.05(20.80–321.00) | 261.29(32.56–910.00) | <0.01 |
| Anti-CCP (U/mL) | 255.7 (21.1–382.0) | 302.2(88.3–500.0) | 0.264 |
| Ig G (g/L) | 11.97±3.21 | 15.42±6.35 | <0.05 |
| Ig A (g/L) | 2.36±1.37 | 3.19±1.93 | <0.05 |
| Ig M (g/L) | 1.05±0.78 | 1.37±0.91 | <0.05 |
| WBC (109/L) | 6.22±2.24 | 6.64±2.74 | 0.270 |
| RBC (1012/L) | 4.37±0.50 | 3.87±0.58 | <0.001 |
| Hb (g/L) | 127.83± 17.55 | 109.08±16.10 | <0.001 |
| HCT (%) | 38.18±6.74 | 35.64±5.22 | <0.01 |
| RDW | 14.40±4.11 | 14.66±2.54 | 0.662 |
| PLT(109/L) | 215.61± 60.95 | 257.00±76.27 | <0.001 |
| PDW | 12.74±3.56 | 12.92±3.98 | 0.754 |
| RPR | 0.022±0.0068 | 0.017±0.0055 | <0.001 |
| HPR | 0.64±0.22 | 0.48±0.18 | <0.001 |
Notes: Patients in inactive group with a DAS 28-CRP score lower than 2.7; active patients with a DAS 28-CRP score of 2.7 and higher.
Abbreviations: DAS28-CRP, Disease Activity Score in 28 joints based on C-reactive protein; F, female; M, male; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide; Ig G, immunoglobulin G; Ig A, immunoglobulin A; Ig M, immunoglobulin M; WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin; HCT, red blood cell specific volume; RDW, red blood cell volume distribution width; PLT, platelet; PDW, platelet volume distribution width; RPR, red blood cells-platelet ratio; HPR, hemoglobin–platelet ratio.
The Diagnostic Value of PLT, RBC, Hb, RPR and HPR for RA
| Parameters | AUC | 95% CI | Optimal Cut-off Value | Specificity (%) | Sensitivity (%) | PPV (%) | NPV (%) | AC (%) |
|---|---|---|---|---|---|---|---|---|
| PLT(109/L) | 0.648 | 0.584–0.709 | >237 | 82.26 | 46.55 | 72.41 | 60.61 | 64.41 |
| RBC (1012/L) | 0.785 | 0.727–0.835 | <4.29 | 77.42 | 72.63 | 76.28 | 73.88 | 75.03 |
| Hb (g/L) | 0.787 | 0.730–0.837 | <128 | 77.42 | 73.74 | 76.56 | 74.67 | 75.58 |
| RPR | 0.747 | 0.687–0.801 | <0.018 | 90.32 | 55.17 | 85.07 | 66.83 | 72.75 |
| HPR | 0.738 | 0.677–0.793 | <0.54 | 83.87 | 55.75 | 77.56 | 65.46 | 69.81 |
Abbreviations: AUC, area under curve; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; AC, accuracy; RBC, red blood cells; Hb, hemoglobin; PLT, platelet; RPR, red blood cells-platelet ratio; HPR, hemoglobin–platelet ratio.
Figure 1Performance of blood RBC, Hb, and PLT in discriminating RA patients from healthy controls. (A) The ROC curves of the three indices in differentiating RA patients from healthy controls. (B) Comparison of ROC curves among the three indices.
The Diagnostic Value of the Markers to Distinguish Active RA from Inactive RA
| Parameters | AUC | 95% CI | Optimal Cut-off Value | Specificity (%) | Sensitivity (%) | PPV (%) | NPV (%) | AC (%) |
|---|---|---|---|---|---|---|---|---|
| PLT(109/L) | 0.666 | 0.591–0.736 | >243 | 73.91 | 56.19 | 68.29 | 62.78 | 65.05 |
| RBC (1012/L) | 0.780 | 0.711–0.839 | <4.22 | 68.12 | 83.96 | 72.48 | 80.94 | 76.04 |
| Hb (g/L) | 0.786 | 0.717–0.844 | <121 | 68.12 | 81.13 | 71.79 | 78.31 | 74.63 |
| RPR | 0.744 | 0.673–0.807 | <0.017 | 68.12 | 74.29 | 69.97 | 72.60 | 71.21 |
| HPR | 0.727 | 0.654–0.791 | <0.48 | 81.16 | 56.19 | 74.89 | 64.94 | 68.68 |
| CRP (mg/L) | 0.749 | 0.678–0.811 | >6.56 | 89.86 | 59.81 | 85.50 | 69.10 | 74.84 |
| ESR (mm/h) | 0.643 | 0.552–0.727 | >44 | 87.27 | 39.13 | 75.45 | 58.91 | 63.20 |
| RF (IU/mL) | 0.572 | 0.495–0.646 | >101 | 76.47 | 43.40 | 64.84 | 57.47 | 59.94 |
| Anti-CCP (U/mL) | 0.544 | 0.455–0.631 | >73.2 | 35.71 | 82.89 | 56.32 | 67.61 | 59.30 |
Abbreviations: AUC, area under curve; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; AC, accuracy; RBC, red blood cells; Hb, hemoglobin; PLT, platelet; RPR, red blood cells-platelet ratio; HPR, hemoglobin–platelet ratio; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide.
Figure 2Performance of blood RBC, Hb, and PLT in discriminating active RA from inactive RA. Comparison of ROC curves between RBC (A), Hb (B) or PLT (C) and other parameters including ESR, CRP, RF and Anti-CCP in differentiating active RA from inactive RA.
Correlations of RBC, Hb, PLT, RPR and HPR with Indices of Disease Activity in RA Patients
| Parameters | CRP (mgL) | ESR (mm/h) | DAS28-CRP | |||
|---|---|---|---|---|---|---|
| r | r | r | ||||
| RBC (1012/L) | −0.289 | <0.001 | −0.481 | <0.001 | −0.428 | <0.001 |
| Hb (g/L) | −0.341 | <0.001 | −0.569 | <0.001 | −0.489 | <0.001 |
| PLT(109/L) | 0.284 | <0.001 | 0.331 | <0.001 | 0.327 | <0.001 |
| RPR | −0.397 | <0.001 | −0.329 | <0.001 | −0.310 | <0.001 |
| HPR | −0.402 | <0.001 | −0.362 | <0.001 | −0.293 | <0.001 |
Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DAS28-CRP, Disease Activity Score in 28 joints based on C-reactive protein; RBC, red blood cells; Hb, hemoglobin; PLT, platelet; RPR, red blood cells-platelet ratio; HPR, hemoglobin–platelet ratio.